P Schoenfeld, M Pimentel, L Chang, A Lembo, W D Chey, J Yu, C Paterson, E Bortey, W P Forbes
BACKGROUND: The efficacy of rifaximin, a nonsystemic, gut-targeted antibiotic for reducing non-constipation-predominant irritable bowel syndrome (non-C IBS) symptoms, has been demonstrated in one phase 2b and two phase 3 randomised, double-blind, placebo-controlled trials, but detailed data about rifaximin safety and tolerability during treatment and subsequent follow-up periods are lacking. AIM: To assess and determine the frequency of rifaximin and placebo adverse events (AEs) in phase 2b and phase 3 non-C IBS trials...
May 2014: Alimentary Pharmacology & Therapeutics